Track A Basic Science

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/138319/1/jia218438.pd

Frequency of obsessive and compulsive symptoms in patients with blepharospasm and hemifacial spasm

BACKGROND: Blepharospasm (BS) is a form of central focal dystonia recently associated with psychiatric disorders, particularly obsessive and compulsive symptoms. Hemifacial spasm (HFS) represents a focal myoclonus with peripheral origin in the facial nerve. OBJECTIVE: To determine the frequency of obsessive and compulsive symptoms in patients with BS in comparison with patients with HFS. METHODS: 30 patients from each group (BS and HFS) followed by the botulinum toxin clinic at the HC-UFPR were evaluated using a structured interview based on the DSM-IV criteria and the Yale-Brown scale. RESULTS: were compared by the mean two-tailed t test. RESULTS: We found obsessive or compulsive symptoms in 20 (66.6%) patients with BE and 21 (70%) with HFS. Yale-Brown scale scores for each group were higher among BS patients; however, diferences were not statisticaly significant. CONCLUSION: Our study did not show a significant diference in the comparison of the prevalence of obsessive and compulsive symptoms among patients with BS and HFS.FUNDAMENTOS: Blefaroespasmo (BE) é uma forma de distonia focal central recentemente relacionada a desordens psiquiátricas, particularmente sintomas obsessivos e compulsivos. Espasmo hemifacial (EHF) representa uma forma de mioclonia com origem periférica, no nervo facial. OBJETIVO: Determinar a frequência de sintomas obsessivos e compulsivos em pacientes com BE em comparação com pacientes com EHF. MÉTODO: Foram avaliados 30 pacientes de cada grupo acompanhados no ambulatório de toxina botulínica do HC-UFPR, através de entrevista estruturada baseada nos critérios do DSM-IV e pela escala de Yale-Brown. Os resultados foram comparados pela média do teste de t de Student bicaudal. RESULTADOS: Observaram-se sintomas obsessivos ou compulsivos em 20 (66,6%) pacientes com BE e 21 (70%) pacientes com EHF. Os escores da escala de Yale-Brown em cada grupo foram maiores entre aqueles com BE, porém, as diferenças não foram estatisticamente significativas. CONCLUSÃO: Nosso estudo não evidenciou diferença significativa na comparação de prevalência de sintomas obsessivos e compulsivos entre pacientes com BE e EHF

Detection of betanodavirus in juvenile barramundi, Lates calcarifer (Bloch), by antigen capture ELISA

10.1111/j.1365-2761.2006.00736.xJournal of Fish Diseases297423-43

The G209a Mutation In The α-synuclein Gene In Brazilian Families With Parkinson's Disease

A missense G209A mutation of the alpha-synuclein gene was recently described in a large Contursi kindred with Parkinson's disease (PD). The objective of this study is to determine if the mutation G209A of the alpha-synuclein gene was present in 10 Brazilian families with PD. PD patients were recruited from movement disorders clinics of Brazil. A family history with two or more affected in relatives was the inclusion criterion for this study. The alpha-synuclein G209A mutation assay was made using polymerase chain reaction and the restriction enzyme Tsp451. Ten patients from 10 unrelated families were studied. The mean age of PD onset was 42.7 years old. We did not find the G209A mutation in our 10 families with PD. Our results suggest that alpha-synuclein mutation G209A is uncommon in Brazilian PD families.593 B722724Polymeropoulos, M.H., Autosomal dominant Parkinson's disease and alpha-synuclein (1998) Ann Neurol, 44 (1 SUPPL.), pp. 63-64Polymeropoulos, M.H., Levadan, C., Leroy, E., Mutation in the alpha-synuclein gene identified in families with Parkinson's disease (1997) Science, 276, pp. 2045-2047Krüger, R., Kühn, W., Muller, T., Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease (1998) Nat Genet, 18, pp. 106-108Chan, P., Tanner, C.M., Jiang, X., Langsten, J.W., Failure to find the alpha-synuclein gene missense mutation (G209A) in 100 patients with younger onset Parkinson's disease (1998) Neurology, 50, pp. 513-514Wang, W.W., Khajavi, M., Patel, B.J., Beach, J., Jankovic, J., Ashizawa, T., The G209A mutation in the α-synuclein gene is not detected in familial cases of Parkinson disease in non-Greek and/or Italian populations (1998) Arch Neurol, 55, pp. 1521-1523Vaughan, Jr., Durr, A., Tassin, J., Bereznai, B., Gasser, T., Bonifati, V., The a-synuclein Ala53Thr mutation is not a common cause of familial Parkinson's disease: A study of 230 European cases (1998) Ann Neurol, 44, pp. 270-273Chan, D.K.Y., Mellich, G., Cai, H., The α-synuclein gene and Parkinson disease in a Chinese population (2000) Arch Neurol, 57, pp. 501-503Gasser, T., Müller-Myhsok, B., Wszolek, Z.K., A susceptibility locus for Parkinson's disease maps to chromosome 2p13 (1998) Nat Genet, 18, pp. 262-265Farrer, M., Gwinn-Hardy, K., Muenter, M., A chromosome 4p haplotype segregating with Parkinson's disease and postural tremor (1999) Hum Mol Genet, 8, pp. 81-85Leroy, E., Boyer, R., Auburger, G., The ubiquitin pathway in Parkinson's disease (1998) Nature, 395, pp. 451-452Kitada, T., Askawa, S., Hattori, N., Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism (1998) Nature, 392, pp. 605-608Gasser, T., Genetics of Parkinson's disease (1998) Ann Neurol, 44 (1 SUPPL.), pp. 53-57Golbe, L.I., Di Iorio, G., Sanges, G., Lazzarini, A.M., LaSala, S., Bonavita, V., Clinical genetic analysis of Parkinson's disease in the Contursi kindred (1996) Ann Neurol, 40, pp. 767-775Gasser, T., Müller-Myhsok, B., Wszolek, Z.K., Genetic complexity and Parkinson's disease (1997) Science, 277, pp. 388-389Bennet, P., Nicholl, D.J., Absence of G209A mutation in alpha-synuclein gene in British families with Parkinson's disease (1998) Neurology, 50, p. 1183Ho, S.L., Kung, M.H.W., G209A mutation in the a-synuclein gene is rare and not associated with sporadic Parkinson's disease (1998) Mov Disord, 13, pp. 970-971Parsian, A., Racette, B., Zhang, Z.H., Mutation, sequence, analysis, and association of a-synuclein in Parkinson's disease (1998) Neurology, 51, pp. 1757-1759Waner, T.T., Schapira, A.H.V., The role of the a-synuclein gene mutation in patients with sporadic Parkinson's disease in the United Kingdom (1998) J Neurol Neurosurg Psychiatry, 65, pp. 378-379Farrer, M., Wavrant-De Vrieze, F., Crook, R., Low frequency of a-synuclein mutations in familial Parkinson's disease (1998) Ann Neurol, 43, pp. 394-397Vaughan, J., Farrer, M.J., Wszolek, Z.K., Sequencing of the alpha-synuclein gene in a large series of case of familial Parkinson's disease fails to reveal any further mutations (1998) Hum Mol Genet, 7, pp. 751-753Lücking, C.B., Dürr, A., Bonifati, V., Association between early-onset Parkinson's disease and mutations in the parkin gene (2000) N Engl J Med, 342, pp. 1560-156

Semiautomated Volumetric Measurement on Postcontrast MR Imaging for Analysis of Recurrent and Residual Disease in Glioblastoma Multiforme

Background and purposeA limitation in postoperative monitoring of patients with glioblastoma is the lack of objective measures to quantify residual and recurrent disease. Automated computer-assisted volumetric analysis of contrast-enhancing tissue represents a potential tool to aid the radiologist in following these patients. In this study, we hypothesize that computer-assisted volumetry will show increased precision and speed over conventional 1D and 2D techniques in assessing residual and/or recurrent tumor.Materials and methodsThis retrospective study included patients with native glioblastomas with MR imaging performed at 24-48 hours following resection and 2-4 months postoperatively. 1D and 2D measurements were performed by 2 neuroradiologists with Certificates of Added Qualification. Volumetry was performed by using manual segmentation and computer-assisted volumetry, which combines region-based active contours and a level set approach. Tumor response was assessed by using established 1D, 2D, and volumetric standards. Manual and computer-assisted volumetry segmentation times were compared. Interobserver correlation was determined among 1D, 2D, and volumetric techniques.ResultsTwenty-nine patients were analyzed. Discrepancy in disease status between 1D and 2D compared with computer-assisted volumetry was 10.3% (3/29) and 17.2% (5/29), respectively. The mean time for segmentation between manual and computer-assisted volumetry techniques was 9.7 minutes and <1 minute, respectively (P < .01). Interobserver correlation was highest for volumetric measurements (0.995; 95% CI, 0.990-0.997) compared with 1D (0.826; 95% CI, 0.695-0.904) and 2D (0.905; 95% CI, 0.828-0.948) measurements.ConclusionsComputer-assisted volumetry provides a reproducible and faster volumetric assessment of enhancing tumor burden, which has implications for monitoring disease progression and quantification of tumor burden in treatment trials